Basic Pharma trusts Arvato Systems to Implement the Falsified Medicines Directive

Production serialization in the pharmaceutical industry

From left to the right: Mr. Piet Meindertsma (Project Manager Basic Pharma), Mr. Oliver Meihorst (Senior Ac-count Manager Pharma Arvato), Mr. Harry Relouw (General Manager & CFO Basic Pharma), Mr. Peter Stemerdink (Key Account Manager Arvato), Mr. Bob Kool (Managing Director Basic Pharma), Mrs. Maja Habets (Manager Production Basic Pharma) and Mr. Anatol Wiebe (Director Arvato Track and Trace) /Copyright:  Arvato Systems / Basic Pharma
(PresseBox) ( Gütersloh, )
  • Arvato Systems and Basic Pharma sign a contract on implementing the Falsified Medicines Directive
  • Basic Pharma, from the Netherlands, uses the Arvato CSDB IT solution for the serialization of prescription drugs
Located in Geleen, the Netherlands, Basic Pharma is well-positioned to serialize its drug packaging, thanks to Arvato Systems’ Arvato CSDB software solution. The contract was signed on 3 November 2017, sealing the cooperation agreement between the two companies.

The European Union adopted the Delegated Regulation to the Falsified Medicines Directive in 2016. Since then, the delegated regulation has been incorporated into the national laws of all E.U. member states. This law is designed to prevent counterfeit medicines from being able to access the European market. Under the new directive, all pharmaceutical packaging must bear a unique identifier (UI). All prescription drug packaging will have to comply with this new requirement starting in February 2019.

The unique identifier for all prescription medicines that are produced in or imported to the European Union are registered in an E.U. database. When a prescription is dispensed from a pharmacy, a system checks whether the unique identifier exists or has not yet been issued. From the generation of the unique identifier to registration at the E.U. level, the entire process takes place at Basic Pharma using Arvato Systems’ Arvato CSDB software solution.

The introduction of the new European system will be monitored in the Netherlands by the Dutch Foundation for the Review of Pharmaceuticals (Stichting Nederlandse Medicijnen Verificatie Organisatie). This organization is implementing the national database, together with Arvato Systems as part of the European system, and will inform all parties about the process.

Basic Pharma has deliberately opted for a solution that ensures smooth integration both with regard to the national and E.U. databases and to (new) production machines.

Arvato CSDB is an integrated and modular IT solution. Communication in the area of serialization can take place at level 3 (control of the production machines), level 4 (own issuing of serialization codes), and level 5 (from national systems to the E.U. Hub as well as to all business partners).

Prepared for the future
Peter Stemerdink, Key Account Manager at Arvato Systems, comments, “We see that too few companies in the Netherlands are actively addressing the importance of the Falsified Medicines Directive, or FMD for short. Implementation requires the adaptation of entire processes, and early implementation is immensely important.”

Harry Relouw, General Manager & CFO of Basic Pharma, is very proud of the fact that his company has taken the lead on the serialization issue: “We are a proactive, process-oriented company that likes to get to the bottom of things and tackle goals. That certainly applies to serialization. We can deal with this drastic change in good time because we have taken sufficient steps to solve this issue ahead of time. By taking this approach, we can assure our clients that there will be no interruptions to the supply of our medicines either today or in the future.”

About Basic Pharma
Basic Pharma is a well-equipped niche player in the pharmaceuticals industry. The company, which is based on the Chemelot campus in Geleen, the Netherlands, is part of the Basic Pharma Group, a group of independent companies that develop, produce, and supply new medicines.
Für die oben stehenden Pressemitteilungen, das angezeigte Event bzw. das Stellenangebot sowie für das angezeigte Bild- und Tonmaterial ist allein der jeweils angegebene Herausgeber (siehe Firmeninfo bei Klick auf Bild/Meldungstitel oder Firmeninfo rechte Spalte) verantwortlich. Dieser ist in der Regel auch Urheber der Pressetexte sowie der angehängten Bild-, Ton- und Informationsmaterialien.
Die Nutzung von hier veröffentlichten Informationen zur Eigeninformation und redaktionellen Weiterverarbeitung ist in der Regel kostenfrei. Bitte klären Sie vor einer Weiterverwendung urheberrechtliche Fragen mit dem angegebenen Herausgeber. Bei Veröffentlichung senden Sie bitte ein Belegexemplar an